Your browser doesn't support javascript.
loading
Preferential association of a functional variant in complement receptor 2 with antibodies to double-stranded DNA.
Zhao, Jian; Giles, Brendan M; Taylor, Rhonda L; Yette, Gabriel A; Lough, Kara M; Ng, Han Leng; Abraham, Lawrence J; Wu, Hui; Kelly, Jennifer A; Glenn, Stuart B; Adler, Adam J; Williams, Adrienne H; Comeau, Mary E; Ziegler, Julie T; Marion, Miranda; Alarcón-Riquelme, Marta E; Alarcón, Graciela S; Anaya, Juan-Manuel; Bae, Sang-Cheol; Kim, Dam; Lee, Hye-Soon; Criswell, Lindsey A; Freedman, Barry I; Gilkeson, Gary S; Guthridge, Joel M; Jacob, Chaim O; James, Judith A; Kamen, Diane L; Merrill, Joan T; Sivils, Kathy Moser; Niewold, Timothy B; Petri, Michelle A; Ramsey-Goldman, Rosalind; Reveille, John D; Scofield, R Hal; Stevens, Anne M; Vilá, Luis M; Vyse, Timothy J; Kaufman, Kenneth M; Harley, John B; Langefeld, Carl D; Gaffney, Patrick M; Brown, Elizabeth E; Edberg, Jeffrey C; Kimberly, Robert P; Ulgiati, Daniela; Tsao, Betty P; Boackle, Susan A.
Afiliação
  • Zhao J; Division of Rheumatology, Department of Medicine, University of California at Los Angeles, Los Angeles, California, USA.
  • Giles BM; Division of Rheumatology, University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Taylor RL; School of Pathology and Laboratory Medicine, Centre for Genetic Origins of Health and Disease, The University of Western Australia, Crawley, Western Australia, Australia.
  • Yette GA; Division of Rheumatology, University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Lough KM; Division of Rheumatology, University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Ng HL; School of Pathology and Laboratory Medicine, Centre for Genetic Origins of Health and Disease, The University of Western Australia, Crawley, Western Australia, Australia.
  • Abraham LJ; School of Pathology and Laboratory Medicine, Centre for Genetic Origins of Health and Disease, The University of Western Australia, Crawley, Western Australia, Australia.
  • Wu H; Division of Rheumatology, Department of Medicine, University of California at Los Angeles, Los Angeles, California, USA.
  • Kelly JA; Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA.
  • Glenn SB; Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA.
  • Adler AJ; Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA.
  • Williams AH; Department of Biostatistical Sciences and Center for Public Health Genomics, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
  • Comeau ME; Department of Biostatistical Sciences and Center for Public Health Genomics, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
  • Ziegler JT; Department of Biostatistical Sciences and Center for Public Health Genomics, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
  • Marion M; Department of Biostatistical Sciences and Center for Public Health Genomics, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
  • Alarcón-Riquelme ME; Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA Pfizer-Universidad de Granada-Junta de Andalucía Center for Genomics and Oncological Research, Granada, Spain.
  • Alarcón GS; Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Anaya JM; Center for Autoimmune Diseases Research (CREA), Universidad del Rosario, Bogotá, Colombia.
  • Bae SC; Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea.
  • Kim D; Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea.
  • Lee HS; Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea.
  • Criswell LA; Rosalind Russell/Ephraim P. Engleman Rheumatology Research Center, University of California San Francisco, San Francisco, California, USA.
  • Freedman BI; Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
  • Gilkeson GS; Division of Rheumatology, Medical University of South Carolina, Charleston, South Carolina, USA.
  • Guthridge JM; Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA.
  • Jacob CO; Department of Medicine, University of Southern California, Los Angeles, California, USA.
  • James JA; Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma
  • Kamen DL; Division of Rheumatology, Medical University of South Carolina, Charleston, South Carolina, USA.
  • Merrill JT; Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA.
  • Sivils KM; Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
  • Niewold TB; Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, Minnesota, USA.
  • Petri MA; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Ramsey-Goldman R; Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  • Reveille JD; Department of Rheumatology and Clinical Immunogenetics, University of Texas Health Science Center at Houston, Houston, Texas, USA.
  • Scofield RH; Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA US Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, USA.
  • Stevens AM; Division of Rheumatology, Department of Pediatrics, University of Washington, Seattle, Washington, USA Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, Washington, USA.
  • Vilá LM; Division of Rheumatology, Department of Medicine, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico.
  • Vyse TJ; Division of Genetics and Molecular Medicine and Immunology, King's College London, London, UK.
  • Kaufman KM; Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA US Department of Veterans Affairs Medical Center, Cincinnati, Ohio, USA.
  • Harley JB; Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA US Department of Veterans Affairs Medical Center, Cincinnati, Ohio, USA.
  • Langefeld CD; Department of Biostatistical Sciences and Center for Public Health Genomics, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
  • Gaffney PM; Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA.
  • Brown EE; Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA Department of Epidemiology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Edberg JC; Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Kimberly RP; Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Ulgiati D; School of Pathology and Laboratory Medicine, Centre for Genetic Origins of Health and Disease, The University of Western Australia, Crawley, Western Australia, Australia.
  • Tsao BP; Division of Rheumatology, Department of Medicine, University of California at Los Angeles, Los Angeles, California, USA.
  • Boackle SA; Division of Rheumatology, University of Colorado School of Medicine, Aurora, Colorado, USA Denver Veterans Affairs Medical Center, Denver, Colorado, USA.
Ann Rheum Dis ; 75(1): 242-52, 2016 Jan.
Article em En | MEDLINE | ID: mdl-25180293
ABSTRACT

OBJECTIVES:

Systemic lupus erythematosus (SLE; OMIM 152700) is characterised by the production of antibodies to nuclear antigens. We previously identified variants in complement receptor 2 (CR2/CD21) that were associated with decreased risk of SLE. This study aimed to identify the causal variant for this association.

METHODS:

Genotyped and imputed genetic variants spanning CR2 were assessed for association with SLE in 15 750 case-control subjects from four ancestral groups. Allele-specific functional effects of associated variants were determined using quantitative real-time PCR, quantitative flow cytometry, electrophoretic mobility shift assay (EMSA) and chromatin immunoprecipitation (ChIP)-PCR.

RESULTS:

The strongest association signal was detected at rs1876453 in intron 1 of CR2 (pmeta=4.2×10(-4), OR 0.85), specifically when subjects were stratified based on the presence of dsDNA autoantibodies (case-control pmeta=7.6×10(-7), OR 0.71; case-only pmeta=1.9×10(-4), OR 0.75). Although allele-specific effects on B cell CR2 mRNA or protein levels were not identified, levels of complement receptor 1 (CR1/CD35) mRNA and protein were significantly higher on B cells of subjects harbouring the minor allele (p=0.0248 and p=0.0006, respectively). The minor allele altered the formation of several DNA protein complexes by EMSA, including one containing CCCTC-binding factor (CTCF), an effect that was confirmed by ChIP-PCR.

CONCLUSIONS:

These data suggest that rs1876453 in CR2 has long-range effects on gene regulation that decrease susceptibility to lupus. Since the minor allele at rs1876453 is preferentially associated with reduced risk of the highly specific dsDNA autoantibodies that are present in preclinical, active and severe lupus, understanding its mechanisms will have important therapeutic implications.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Assunto principal: Anticorpos Antinucleares / Receptores de Complemento 3d / Lúpus Eritematoso Sistêmico Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Humans / Middle aged Idioma: En Revista: Ann Rheum Dis Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Temas: Geral Base de dados: MEDLINE Assunto principal: Anticorpos Antinucleares / Receptores de Complemento 3d / Lúpus Eritematoso Sistêmico Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Humans / Middle aged Idioma: En Revista: Ann Rheum Dis Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Estados Unidos